Showing results (271-280 of 303) with videos related to
Sort By:
Pageof 31
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.Cell Reports|July 27, 2017
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor EvolutionGrace R Anderson, Peter S Winter, Kevin H Lin, et al.Cancer Cell|November 14, 2018
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory MechanismAngelina V Vaseva, Devon R Blake, Thomas S K Gilbert, et al.Nature Communications|November 4, 2022
Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translationBartosz Mucha, Shuo Qie, Sagar Bajpai, et al.NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.Cancer Research|April 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic CancerRavi Thakur, Dezhen Wang, Tuo Hu, et al.Journal of Medicinal Chemistry|June 12, 2019
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid LeukemiaNagore I Marín-Ramos, Moisés Balabasquer, Francisco J Ortega-Nogales, et al.Cancer Discovery|April 29, 2020
Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic CancerSeth J Parker, Caroline R Amendola, Kate E R Hollinshead, et al.Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRASQ61 mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.Pageof 31